These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1906019)

  • 21. Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles.
    Fluker MR; Hooper WM; Yuzpe AA
    Fertil Steril; 1999 Feb; 71(2):294-301. PubMed ID: 9988401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian 11 beta-hydroxysteroid dehydrogenase activity is inversely related to the outcome of in vitro fertilization-embryo transfer treatment cycles.
    Michael AE; Gregory L; Piercy EC; Walker SM; Shaw RW; Cooke BA
    Fertil Steril; 1995 Sep; 64(3):590-8. PubMed ID: 7641915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
    Lee KL; Couchman GM; Walmer DK
    J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles.
    Van Wely M; Westergaard LG; Bossuyt PM; Van der Veen F
    Cochrane Database Syst Rev; 2003; (1):CD003973. PubMed ID: 12535497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cycle-specific and cumulative fecundity in patients with endometriosis who are undergoing controlled ovarian hyperstimulation-intrauterine insemination or in vitro fertilization-embryo transfer.
    Dmowski WP; Pry M; Ding J; Rana N
    Fertil Steril; 2002 Oct; 78(4):750-6. PubMed ID: 12372451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled ovarian hyperstimulation does not adversely affect endometrial receptivity in in vitro fertilization cycles.
    Levi AJ; Drews MR; Bergh PA; Miller BT; Scott RT
    Fertil Steril; 2001 Oct; 76(4):670-4. PubMed ID: 11591397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproducibility and clinical significance of pre-ovulatory serum progesterone level and progesterone/estradiol ratio on the day of human chorionic gonadotropin administration in infertile women undergoing repeated in vitro fertilization cycles.
    Lin YJ; Lan KC; Huang FJ; Lin PY; Chiang HJ; Kung FT
    Reprod Biol Endocrinol; 2015 May; 13():41. PubMed ID: 25967104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome.
    Jäger W; Diedrich K; Wildt L
    Fertil Steril; 1987 Oct; 48(4):675-8. PubMed ID: 3115839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins.
    Caspi E; Ron-El R; Golan A; Nachum H; Herman A; Soffer Y; Weinraub Z
    Fertil Steril; 1989 Jan; 51(1):95-9. PubMed ID: 2521328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of human menopausal gonadotropin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation.
    Aboulghar MA; Mansour RT; Serour GI; Rhodes CA; Amin YM
    J Assist Reprod Genet; 2000 May; 17(5):298-301. PubMed ID: 10976419
    [No Abstract]   [Full Text] [Related]  

  • 32. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment variables in relation to oocyte maturation: lessons from a clinical micromanipulation-assisted in vitro fertilization program.
    Avrech OM; Goldman GA; Rufas O; Stein A; Amit S; Yoles I; Pinkas H; Fisch B
    J Assist Reprod Genet; 1997 Jul; 14(6):337-42. PubMed ID: 9226513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
    Younis JS; Simon A; Koren R; Dorembus D; Schenker JG; Laufer N
    Fertil Steril; 1992 Sep; 58(3):575-80. PubMed ID: 1387849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios.
    Groen H; Tonch N; Simons AH; van der Veen F; Hoek A; Land JA
    Hum Reprod; 2013 Dec; 28(12):3236-46. PubMed ID: 24166594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of baseline ovarian cysts on the clinical response to controlled ovarian hyperstimulation in an in vitro fertilization program.
    Hornstein MD; Barbieri RL; Ravnikar VA; McShane PM
    Fertil Steril; 1989 Sep; 52(3):437-40. PubMed ID: 2673843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent ovarian cysts following administration of human menopausal and chorionic gonadotropins: an attenuated form of ovarian hyperstimulation syndrome.
    Tummon IS; Henig I; Radwanska E; Binor Z; Rawlins R; Dmowski WP
    Fertil Steril; 1988 Feb; 49(2):244-8. PubMed ID: 3123275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of 17 beta-estradiol levels in highly responding women during ovulation induction in IVF treatment: its impact and prognostic value with respect to oocyte maturation and treatment outcome.
    Ben-Nun I; Shulman A; Ghetler Y; Shilon M; Kaneti H; Beyth Y
    J Assist Reprod Genet; 1993 Apr; 10(3):213-5. PubMed ID: 8400733
    [No Abstract]   [Full Text] [Related]  

  • 39. Delaying human chorionic gonadotropin administration in human menopausal gonadotropin-induced cycles decreases successful in vitro fertilization of human oocytes.
    Laufer N; DeCherney AH; Tarlatzis BC; Zuckerman AL; Polan ML; Dlugi AM; Graebe R; Barnea ER; Naftolin F
    Fertil Steril; 1984 Aug; 42(2):198-203. PubMed ID: 6430722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.